ClearPoint Neuro Inc. — Earnings Quality Grade F
CLPT · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 65 days, change +10 days YoY
AR outpaced revenue for 2 consecutive years
Revenue grew 17.8% but CFFO declined -167.3%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
Inventory 21.8% vs COGS 16.4%. Normal
CapEx growth 89.8% is >2x revenue growth 17.8%
SG&A/Gross Profit = 145.2%, exceeds 70%
Gross margin 61.4%, change +0.5pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -1.7%. Low accruals
Cash $0.0B covers 79% of debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 76% of equity. Over 50%
Interest coverage = -10.1x (<2x). Financial stress
Other assets grew 131.6% vs revenue 17.8%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles surged 4320% YoY
Manipulation Score
M-Score = 2.08 (> -1.78). LIKELY MANIPULATOR
Small-cap context: Beneish M-Score was calibrated on large-caps; small-cap DSO/inventory volatility mechanically inflates it.
Portfolio monitoring
Monitor CLPT continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25